Tag: CAR-T therapy
-
Latin America’s First Homegrown CAR: A New Era for Brazil’s Public Health
A Historic Milestone in Latin American Healthcare Latin America is witnessing a landmark achievement as the Nutera Center in Ribeirão Preto launches the region’s first homegrown CAR-T (Chimeric Antigen Receptor T-cell) cancer therapy program. Backed by substantial public investment, the initiative aims to transform how Brazil’s public health system delivers cutting-edge oncology care, potentially lowering…
-
Latin America’s First Homegrown CAR: How Nutera Center Aims to Transform Cancer Care in Brazil
Overview: A Milestone in Latin American Healthcare Brazil is making a historic leap in cancer treatment with the launch of Latin America’s first homegrown Chimeric Antigen Receptor (CAR) T therapy program. The Nutera Center in Ribeirão Preto has unveiled a groundbreaking clinical initiative backed by substantial public investment and partnerships across the health and research…
-
NICE Recommends AUCATZYL (obecabtagene autoleucel) for UK patients
Summary: NICE backs AUCATZYL for eligible patients The National Institute for Health and Care Excellence (NICE) has recommended AUCATZYL, the CAR-T cell therapy obatabtagene autoleucel (also known as obecabtagene autoleucel), for use within the UK’s healthcare system. The decision marks a significant milestone for patients with certain hematologic cancers and highlights the growing role of…
-
NICE Recommends AUCATZYL® (obecabtagene autoleucel) for Wider Patient Access in the UK
Overview: NICE Endorses AUCATZYL for Expanded Use The National Institute for Health and Care Excellence (NICE) has recommended AUCATZYL® (obecabtagene autoleucel) for a broader patient population in the United Kingdom. This decision follows a rigorous review of clinical data, cost-effectiveness, and real-world impact on NHS services. AUCATZYL is a next-generation CAR-T therapy designed to harness…
-
NICE Recommends AUCATZYL for CAR-T Therapy: What It Means for Patients
Introduction: A pivotal NICE Recommendation The National Institute for Health and Care Excellence (NICE) has endorsed AUCATZYL (obecabtagene autoleucel) for use in eligible patients, signaling a major milestone for CAR-T cell therapy in the healthcare system. This endorsement places AUCATZYL among the select therapies that have gained formal approval for coverage and reimbursement, potentially expanding…
-
Immune Complications Elevate Infection Risk in MM Therapies
Overview: Why Immune Complications Matter in Advanced Multiple Myeloma Therapies Chimeric Antigen Receptor (CAR-T) cell therapy and bispecific antibodies (BsAbs) have transformed the treatment landscape for multiple myeloma (MM), offering deep and durable responses for patients with relapsed or refractory disease. Yet, these immune-based therapies also bring new challenges. Immune complications, including impaired humoral and…